痰热清注射液对肺癌合并肺部感染患者呼吸症状及血液感染指标的影响  

Effects of Tanreqing Injection on Respiratory Symptoms and Blood Infection Indexes in Patients with Lung Cancer Complicated with Pulmonary Infection

作　　者：韦伟[1] 李强 任君清 吴伟 孙军[1] WEI Wei;LI Qiang;REN Jun-qing;WU Wei;SUN Jun(Xuancheng People's Hospital,Xuancheng Anhui 242000)

机构地区：[1]安徽省宣城市人民医院,安徽宣城242000

出　　处：《世界中西医结合杂志》2022年第4期811-815,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：安徽省卫生厅中医院科研计划(1292SK2019B08)。

摘　　要：目的探讨痰热清注射液对肺癌合并肺部感染患者呼吸症状及血液感染指标的影响。方法选取2019年1月—2020年6月期间安徽省宣城市人民医院收治的肺癌合并肺部感染病患者92例,按照随机数字表法分为观察组和对照组,每组各46例。对照组给予常规支持治疗+头孢哌酮钠舒巴坦钠静脉滴注治疗+氨溴索注射液静脉滴注治疗,观察组在对照组基础上采用痰热清注射液静脉滴注治疗。治疗2周后,观察比较两组患者治疗前后呼吸症状积分、临床肺部感染评分(Clinical pulmonary infection score,CPIS)、卡氏评分(KPS评分)及血液感染指标[降钙素原(procalcitonin,PCT)、C反应蛋白(C-reactive protein,CRP)、白细胞计数(White blood cell count,WBC)、中性粒细胞比例(Neutrophil,NEU)]改善状况,比较两组患者临床疗效、临床症状持续时间及不良反应发生情况。结果两组患者治疗后咳嗽、咳痰、气息粗促、痰血、胸闷、胸痛等积分均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组各症状积分明显低于对照组,差异有统计学意义(P<0.05)。两组患者治疗后CPIS评分均较治疗前明显降低,KPS评分均较治疗前明显升高,差异有统计学意义(P<0.05);且观察组CPIS、KPS评分改善均明显优于对照组,差异有统计学意义(P<0.05)。治疗后观察组发热时间、咳痰时间、咳嗽时间、肺啰音时间均明显低于对照组,差异有统计学意义(P<0.05)。两组患者治疗后血液感染PCT、CRP、WBC、NEU指标均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组PCT、CRP、WBC、NEU指标均明显低于对照组,差异有统计学意义(P<0.05)。治疗后观察组总有效率93.5%(43/46)明显高于对照组78.3%(36/46),差异有统计学意义(P<0.05)。治疗期间观察组不良反应发生率为8.7%(4/46),明显低于对照组23.9%(11/46),两组比较差异有统计学意义(P<0.05)。结论痰热清注射液能够改善肺癌合并�Objective To observe the effects of Tanreqing Injection on respiratory symptoms and blood infection indexes in patients with lung cancer complicated with pulmonary infection.Methods Ninety-two patients with lung cancer complicated with pulmonary infection treated in Xuancheng People′s Hospital of Anhui Province from January 2019 to June 2020 were enrolled and divided into an observation group(n=46)and a control group(n=46)according to a random number table.The patients in the control group received routine supportive treatment+cefoperazone sodium and sulbactam sodium(i.v.drip)+ambroxol injection(i.v.drip),while those in the observation group received additional Tanreqing Injection(i.v.drip)on the basis of the therapeutic protocol of the control group.After two weeks of treatment,the improvement of respiratory symptom score,clinical pulmonary infection score(CPIS),Karnofsky Performance Scale(KPS)score,and blood infection indexes[procalcitonin(PCT),C-reactive protein(CRP),white blood cell count(WBC),and neutrophil(NEU)]in both groups before and after treatment was observed and compared.The clinical efficacy,duration of clinical symptoms,and adverse events were compared between the two groups.Results After treatment,the scores of cough,expectoration,rough breathing and shortness of breath,bloody phlegm,chest tightness,and chest pain in the two groups were lower than those before treatment(P<0.05),and the above symptom scores of the observation group were lower than those of the control group(P<0.05).After treatment,the CPIS was lower and the KPS score was higher in thetwo groups than those before treatment(P<0.05),and the observation group was superior to the control group in improving CPIS and KPS score(P<0.05).The post-treatment fever time,expectoration time,cough time,and pulmonary rale time in the observation group were shorter than those in the control group(P<0.05).The blood infection indexes,such as PCT,CRP,WBC,and NEU in the two groups were lower than those before treatment(P<0.05),and the above indexes in

关 键 词：肺癌合并肺部感染 痰热清注射液 呼吸症状 感染指标 

分 类 号：R734.2[医药卫生—肿瘤]